New molecular targets in melanoma

被引：17

作者：

Flaherty, KT ^{[1
]}

Brose, MS ^{[1
]}

机构：

[1] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

CURRENT OPINION IN ONCOLOGY | 2004年 / 16卷 / 02期

关键词：

melanoma; molecular targets; metastasis;

D O I：

10.1097/00001622-200403000-00012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic melanoma remains a disease with few therapeutic options and no regimen that prolongs survival. Peptide and whole-cell vaccines that use cell surface proteins unique to melanoma to engender a specific immune response have not been associated with significant antitumor activity in patients with unresectable metastatic disease. The commonly used chemotherapeutic agents have limited efficacy and do not capitalize on abnormalities that are unique to melanoma [1]. Therapies that target the molecular pathophysiology of metastatic melanoma provide hope that more effective treatments will soon be available.

引用

页码：150 / 154

页数：5

共 32 条

[1]

Adjei AA, 2000, CANCER RES, V60, P1871

[2]

BELLI B, 2003, P AACR, P44

[3] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].

Bergers, G ;

Song, S ;

Meyer-Morse, N ;

Bergsland, E ;

Hanahan, D .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295

[4]

Brose MS, 2002, CANCER RES, V62, P6997

[5] Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation [J].

Busca, R ;

Bertolotto, C ;

Ortonne, JP ;

Ballotti, R .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (50) :31824-31830

[6]

Carson WE, 2003, P AN M AM SOC CLIN, V22, P715

[7]

CHAN S, 2003, P AN M AM SOC CLIN, V22, P193

[8]

CHOI YJ, 2003, J AACR, V44, P138

[9] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[10] Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer [J].

Eisen, T ;

Boshoff, C ;

Mak, I ;

Sapunar, F ;

Vaughan, MM ;

Pyle, L ;

Johnston, SRD ;

Ahern, R ;

Smith, IE ;

Gore, ME .

BRITISH JOURNAL OF CANCER, 2000, 82 (04) :812-817

← 1 2 3 4 →